Home » Stocks » Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc. (RIGL)

Stock Price: $2.45 USD -0.06 (-2.39%)
Updated Aug 14, 2020 10:49 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 413.88M
Revenue (ttm) 108.04M
Net Income (ttm) -25.02M
Shares Out 168.93M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $2.45
Previous Close $2.51
Change ($) -0.06
Change (%) -2.39%
Day's Open 2.51
Day's Range 2.44 - 2.53
Day's Volume 651,374
52-Week Range 1.23 - 5.24

More Stats

Market Cap 413.88M
Enterprise Value 364.50M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 168.93M
Float 168.41M
EPS (basic) -0.14
EPS (diluted) -0.15
FCF / Share -0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 15.19M
Short Ratio 0.50
Short % of Float 5.88%
Beta 1.35
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.83
PB Ratio 6.68
Revenue 108.04M
Operating Income -25.74M
Net Income -25.02M
Free Cash Flow -42.95M
Net Cash 49.38M
Net Cash / Share 0.29
Gross Margin 5.09%
Operating Margin -23.82%
Profit Margin -23.20%
FCF Margin -39.75%
ROA -10.94%
ROE -35.37%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$7.14*
(191.43% upside)
Low
5.00
Current: $2.45
High
8.00
Target: 7.14
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue59.2944.514.4820.3828.908.257.152.254.75125
Revenue Growth33.2%892.62%-78%-29.46%250.24%15.38%217.78%-52.63%-96.2%-
Gross Profit58.3844.224.4820.3828.908.257.152.254.75125
Operating Income-69.09-72.68-78.88-69.65-51.69-91.15-89.45-99.36-86.3735.32
Net Income-66.89-70.48-77.99-69.22-51.46-90.91-89.03-98.84-85.9737.89
Shares Outstanding16716112694.3988.4387.6687.2974.9763.3352.06
Earnings Per Share-0.40-0.44-0.62-0.73-0.58-1.04-1.02-1.32-1.360.72
Operating Cash Flow-41.51-58.83-77.56-75.89-23.41-69.75-86.08-85.21-69.3846.74
Capital Expenditures-1.46-1.110.57-0.72-0.49-0.18-1.21-3.36-2.30-3.56
Free Cash Flow-42.97-59.93-76.99-76.61-23.90-69.93-87.28-88.57-71.6843.18
Cash & Equivalents98.0812911674.77126143212298248177
Total Debt36.31--------0.80
Net Cash / Debt61.7712911674.77126143212298248176
Assets14813911978.13132154226310257187
Liabilities93.7529.2318.4723.1140.3725.8917.8120.9520.9620.56
Book Value53.8211010155.0391.38128208289236166
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rigel Pharmaceuticals, Inc.
Country United States
Employees 163
CEO Raul R. Rodriguez

Stock Information

Ticker Symbol RIGL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RIGL
IPO Date November 29, 2000

Description

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.